Results 41 to 50 of about 7,464 (222)

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study [PDF]

, 2016
BACKGROUND: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E ...
Abram, Michael E., Arribas, Jose R., Avihingsanon, Anchalee, Benson, Paul, Bloch, Mark, Cheng, Andrew, Chetchotisakd, Ploenchan, Crofoot, Gordon, Custodio, Joseph M., Fordyce, Marshall W., Gathe, Joseph, Gupta, Samir K., Lichtenstein, Kenneth, McCallister, Scott, Post, Frank A., Pozniak, Anton, Ramgopal, Moti, SenGupta, Devi, Wei, Xuelian   +18 more
core   +1 more source

The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental Schistosoma mansoni infection in mice

Scientific Reports, 2021
Schistosoma mansoni is less susceptible to the antiparasitic drug ivermectin than other helminths. By inhibiting the P-glycoprotein or cytochrome P450 3A in mice host or parasites in a murine model, we aimed at increasing the sensitivity of S. mansoni to
Belén Vicente, Julio López-Abán, Juliane Chaccour, Juan Hernández-Goenaga, Patricia Nicolas, Pedro Fernández-Soto, Antonio Muro, Carlos Chaccour   +7 more
doaj   +1 more source

Aspectos farmacológicos de darunavir/cobicistat

Enfermedades Infecciosas y Microbiología Clínica, 2016
Rezolsta® (darunavir/cobicistat) es el primer inhibidor de la proteasa potenciado en combinación fija con un nuevo potenciador farmacológico. Darunavir es actualmente el inhibidor de la proteasa de uso preferente con un perfil de eficacia y seguridad bien conocido.
González-Doménech, Carmen María, Palacios-Muñoz, María Rosario, Santos-González, Jesús Leandro   +2 more
openaire   +3 more sources

Week 48 resistance analyses of the once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials [PDF]

, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed ...
Ajana, F, Antela, A, Antinori, A, Arasteh, K, Arribas, JR, Baugh, Bryan, Belonosova, E, Benson, P, Berenguer, J, Bhatti, L, Bickel, M, Bogner, J, Bredeek, F, Brown, Kimberley, Brunetta, J, Casado, J, Castelli, F, Chernova, O, Chirianni, A, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, De Los Santos, I, De Luca, A, De Meyer, Sandra, De Wit, S, DeJesus, E, deVente, J, Di Biagio, A, Dushkina, N, Eron, J, Esser, S, Estrada, V, Faetkenheuer, G, Felizarta, F, Florence, E, Franco, R, Galindo, MJ, Gallant, J, Galli, M, Garcia Del Toro, M, Garlicki, A, Gasiorowski, J, Gatell, JM, Gazzard, BG, Ghys, Anne, Girard, P-M, Gorgolas, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henry, K, Horban, A, Jayaweera, D, Jessen, H, Jezorwski, John, Johnson, MA, Katlama, C, Kern, W, Klein, M, Kulagin, V, Lathouwers, Erkki, Lazzarin, A, Lucasti, C, Maggiolo, F, Martorell, C, Maserati, R, McDonald, C, McGowan, J, Mills, A, Mohsine, El Ghazi, Molina, J-M, Morales-Ramirez, J, Moutschen, M, Murphy, D, Mussini, C, Negredo, E, Opsomer, Magda, Orkin, C, Parczewski, M, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Prelutsky, D, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Reeves, I, Rey, D, Reynes, J, Rivero, A, Rockstroh, J, Ruane, P, Rubio, R, Ryamova, E, Shafran, S, Shuldyakov, A, Sizova, N, Slim, J, Spinner, C, Stellbrink, H-J, Stoehr, A, Teicher, E, Tsybakova, O, Van Landuyt, Erika, Van Wijngaerden, E, Vandekerckhove, L, Vandercam, B, Vekerckhove, L, Vercam, B, Viciana, P, Voronin, E, Walmsley, S, Waters, L, Wilkin, A, Wong, Eric Y, Yakovlev, A, Yazdanpanah, Y   +123 more
core   +3 more sources

Rhabdomyolysis in an HIV cohort: epidemiology, causes and outcomes. [PDF]

, 2017
BackgroundThe Literature on rhabdomyolysis in the HIV-positive population is sparse and limited. We aimed to explore the incidence, patient characteristics, etiologies and outcomes of rhabdomyolysis in a cohort of HIV-positive patients identified through
Atta, Mohamed G, Estrella, Michelle M, Fine, Derek M, Koubar, Sahar H, Lucas, Gregory M, Moore, Richard D, Warrier, Rugmini   +6 more
core   +1 more source

Lack of antiviral activity of darunavir against SARS-CoV-2

International Journal of Infectious Diseases, 2020
Objectives: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are ...
Sandra De Meyer, Denisa Bojkova, Jindrich Cinatl, Ellen Van Damme, Christophe Buyck, Marnix Van Loock, Brian Woodfall, Sandra Ciesek   +7 more
doaj   +1 more source

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review

Pharmaceutics, 2023
Background: The clinical outcomes of antiretroviral drugs may be modified through drug interactions; thus, it is important to update the drug interactions in people living with HIV (PLHIV). Aim: To update clinically relevant drug interactions in PLHIV on
Pedro Amariles, Mónica Rivera-Cadavid, Mauricio Ceballos   +2 more
doaj   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh, Julia C. Stingl, Marco Stadler, Anja Reichert, Heiner Wedemeyer, Johannes Oldenburg   +5 more
wiley   +1 more source

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, EarlyView.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source